Genomic Vision Completes First Milestone in Sanofi Genzyme Deal
Source: nan bkk/Getty Images
May 17, 2021
Share
Genomic Vision
reported that the company successfully completed work-package-one of a three-part research agreement for the genetic characterization of Sanofi cell banks. Two years ago, Genomic Vision began part one of partnership with Sanofi Genzyme to characterize transformed cell lines for bioproduction and to compare proprietary molecular combing technology with other laboratory methods.
Genomic Vision officials said results paved the way to a better understanding of the genetic characterization of transformed cell lines. Company scientists applied their molecular combing method, which involves a single DNA molecule analysis technology using the FiberVision
Genomic Vision Announce the Pursuit of Its Partnership With Sanofi and the Successful Completion of Its First Milestone
Genomic Vision
(the Company FR0011799907 GV), a biotechnology company that develops tools and services dedicated to the analysis and control of changes in the genome, today announces that they have successfully completed work package one of a three-part research agreement for the genetic characterization of Sanofi cell banks.
In 2019 Genomic Vision started the first part of a partnership with Sanofi Genzyme (the specialty care global business unit of Sanofi), to characterize transformed cell lines for bio-production and to compare proprietary molecular combing technology with other laboratory methods
Genomic Vision: 2020 Annual Results
Good control of current operating expenses (-5.0%)
27% reduction in cash burn compared with 2019
Current financial resources offer visibility for the next 12 months
Regulatory News:
Genomic Vision
(FR0011799907 GV) (Paris:GV), a biotechnology company that develops tools and services dedicated to the analysis and control of changes in the genome, today reported its annual financial results for the year to December 31, 2020
1
(24)
2020
sales (€1,084 thousand) were down 39% compared to December 31, 2019, notably as a result of a fall in platform sales (1 platform sold in 2020 versus 4 in 2019), the non-renewal of the license granted to Quest Diagnostics, which had generated revenue of €250 thousand the previous year, and the slowdown in commercial activity resulting from the Covid-19 crisis. In particular, the number of orders of consumables fell with most clients closing sites in the second quarter of 2020.
Genomic Vision appoints Mark David Lynch as Global Commercial and Marketing Director
BAGNEUX, France (BUSINESS WIRE) Regulatory News:
Genomic Vision
(Paris:GV)
(the “Company” - FR0011799907 – GV), a biotechnology company that develops tools and services dedicated to the analysis and control of changes in the genome, today announces the appointment of Mark David Lynch as Global Commercial and Marketing Director.
Graduated in microbiology from University of Glasgow, Mark David Lynch has extensive experience in the business development of research and diagnostic devices.
Prior to joining Genomic Vision, Mark spent nearly 10 years at Fluidigm Corporation, a US biotechnology company, where he held different senior management positions, before becoming Head of Sales & Support. He was instrumental in the Company’s expansion, with substantial contribution to the growth of its microfluids business in the US market in 2020. During his career at Fluidigm,
Genomic Vision appoints Mark David Lynch as Global Commercial and Marketing Director
(Paris:GV)
(the Company FR0011799907 GV), a biotechnology company that develops tools and services dedicated to the analysis and control of changes in the genome, today announces the appointment of Mark David Lynch as Global Commercial and Marketing Director.
Graduated in microbiology from University of Glasgow, Mark David Lynch has extensive experience in the business development of research and diagnostic devices.
Prior to joining Genomic Vision, Mark spent nearly 10 years at Fluidigm Corporation, a US biotechnology company, where he held different senior management positions, before becoming Head of Sales Support. He was instrumental in the Company s expansion, with substantial contribution to the growth of its microfluids business in the US market in 2020. During his career at Fluidigm, Mark has received several performance-related company awards.